|
Jun 2
|
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
|
|
Jun 2
|
Ipsen S.A. - Initiation of the share buy-back program
|
|
May 31
|
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
|
|
May 7
|
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis
|
|
May 6
|
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
|
|
Apr 24
|
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
|
|
Feb 14
|
Ipsen SA (IPSEF) Full Year 2024 Earnings Call Highlights: Strong Sales Growth and Strategic ...
|
|
Feb 13
|
Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
|